John Butler, Akebia CEO

Ake­bia touts new da­ta on ane­mia drug a year af­ter re­jec­tion

Ake­bia Ther­a­peu­tics is back with more da­ta on its ex­per­i­men­tal ane­mia drug vadadu­s­tat fol­low­ing a CRL from the FDA last year and the end of its part­ner­ship with Ot­su­ka.

The biotech an­nounced on Mon­day that vadadu­s­tat proved non-in­fe­ri­or to Roche and Vi­for’s long-act­ing ery­thro­poiesis-stim­u­lat­ing agent (ESA) Mircera when ad­min­is­tered three times a week for the main­te­nance treat­ment of ane­mia in pa­tients on dial­y­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.